Display options
Cite
Garrote H, de la Fuente A, Oña R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015;4:8doi: 10.1186/s40164-015-0003-4.
Garrote, H., de la Fuente, A., Oña, R., Rodríguez, I., Echevarría, J. E., Sepúlveda, J. M., & García, J. F. (2015). Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Experimental hematology & oncology, 48. https://doi.org/10.1186/s40164-015-0003-4
Garrote, Heidys, et al. "Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia." Experimental hematology & oncology vol. 4 (2015): 8. doi: https://doi.org/10.1186/s40164-015-0003-4
Garrote H, de la Fuente A, Oña R, Rodríguez I, Echevarría JE, Sepúlveda JM, García JF. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015. PMID: 25767742; PMCID: PMC4357158.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015.

Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia.

Experimental hematology & oncology

Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría, Juan M Sepúlveda, Juan F García

Affiliations

  1. Department of Translational Research, MD Anderson Cancer Center Madrid, Madrid, Spain.
  2. Department of Hematology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  3. Department of Radiology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  4. Department of Virology, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain ; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  5. Department of Neurology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  6. Department of Translational Research, MD Anderson Cancer Center Madrid, Madrid, Spain ; Department of Pathology, MD Anderson Cancer Center, Madrid, Spain.

PMID: 25767742 PMCID: PMC4357158 DOI: 10.1186/s40164-015-0003-4

Abstract

A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and rituximab, which produced a complete remission. Eight months after the last dose of rituximab he had visual disturbance, diminished muscular strength in the right arm and vesicular-papular lesions in the left ophthalmic branch region of the V cranial nerve. These were initially interpreted as herpes virus encephalopathy (HVE), but brain magnetic resonance imaging (MRI) showed evidence of demyelination consistent with progressive multifocal leukoencephalopathy (PML). Cerebrospinal fluid (CSF) analysis was negative for varicella zoster virus (VZV) and John Cunningham virus (JCV) DNA. The clinical suggestion of PML prompted us to perform a brain biopsy and to start treatment with mefloquine. In the brain biopsy, histopathological features of demyelination were described and the polymerase chain reaction (PCR) identified JCV, confirming the diagnosis of PML. Treatment with mefloquine (250 mg/week) and dexamethasone (4 mg/day) was started and maintained for 6 months. A year later there was an almost complete resolution of the MRI lesions and the patient achieved a stable clinical state with persisting motor impairment and severe epilepsy. The patient is alive 38 months after diagnosis of PML, which is the longest known survival to date.

Keywords: Demyelization; Immune system suppression; John Cunningham virus; Progressive multifocal leukoencephalopathy

References

  1. Antimicrob Agents Chemother. 2009 May;53(5):1840-9 - PubMed
  2. Cancer. 2014 Aug 15;120(16):2464-71 - PubMed
  3. Br J Haematol. 2014 Nov;167(4):570-1 - PubMed
  4. Lancet Neurol. 2009 Jan;8(1):28-31 - PubMed
  5. Neurology. 2013 Apr 9;80(15):1430-8 - PubMed
  6. Lancet Neurol. 2010 Apr;9(4):425-37 - PubMed
  7. Blood. 2009 May 14;113(20):4834-40 - PubMed
  8. J Clin Oncol. 2014 Mar 20;32(9):e33-4 - PubMed
  9. J Neurovirol. 2013 Aug;19(4):351-8 - PubMed
  10. BMJ Case Rep. 2014 Jan 08;2014:null - PubMed
  11. Brain. 1958 Mar;81(1):93-111 - PubMed

Publication Types